Cannabis use in adolescence is emerging as a risk factor for the development of psychosis. In animal studies, Δ9-tetrahydrocannabinol (THC), the psychoactive component of cannabis, modulates striatal dopaminergic neurotransmission. Alterations in human striatal dopaminergic function have also been reported both in psychosis and in stimulant use. We sought to examine whether striatal dopamine D2/D3 receptor availability was altered in volunteers with a history of cannabis use using a database of previously acquired [11C]-raclopride positron emission tomography (PET) scans. Ten [11C]-raclopride scans from volunteers with a history of cannabis use were compared to ten control scans using a functional striatal subdivision region of interest (ROI) analysis. No significant differences in either overall striatal BPND values or BPND values in any functional striatal subdivision were found between the two groups. There was also no correlation between lifetime frequency of cannabis use and BPND values. Limbic striatal BPND values were ten percent lower in current nicotine cigarette smokers. These findings suggest that, unlike other drugs of abuse, a history of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability.
AmeriA (1999) The effects of cannabinoids on the brain. Prog Neurobiol58: 315–348.
2.
BarkusEMorrisonPDVuleticDDicksonJEllPJPilowskyLS. (2010) Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol25: 1462–1468.
3.
BarkusEJStirlingJHopkinsRSLewisS (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology39: 175–178.
4.
BossongMGvan BerckelBNBoellaardRZuurmanLSchuitRCWindhorstAD. (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsycho pharmacology34: 759–766.
5.
BrodyALMandelkernMAOlmsteadREAllen-MartinezZScheibalDAbramsAL. (2009) Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology34: 282–289.
CarsonREBreierAde BartolomeisASaundersRCSuTPSchmallB. (1997) Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab17: 437–447.
8.
ChawlaS (2006) World Drug Report 2006. New York City, NY: United Nations Office on Drugs and Crime.
9.
CheerJFWassumKMHeienMLPhillipsPEWightmanRM (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci24: 4393–4400.
10.
DaltonVSZavitsanouK (2010) Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain. J Chem Neuroanat40: 272–280.
11.
de la Fuente-FernandezRRuthTJSossiVSchulzerMCalneDBStoesslAJ (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science293: 1164–1166.
12.
EgertonAShotboltJPStokesPRHiraniEAhmadRLappinJM. (2010) Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study. Neuroimage50: 260–266.
13.
FehrCYakushevIHohmannNBuchholzHGLandvogtCDeckersH. (2008) Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry165: 507–514.
14.
FerrariFOttaniAGiulianiD (1999) Influence of the cannabinoid agonist HU 210 on cocaine- and CQP 201-403-induced behavioural effects in rat. Life Sci65: 823–831.
GrechAVan OsJJonesPBLewisSWMurrayRM (2005) Cannabis use and outcome of recent onset psychosis. Eur Psychiatry20: 349–353.
17.
Higuera-MatasABotreauFDel OlmoNMiguensMOliasOMontoyaGL. (2010) Periadolescent exposure to cannabinoids alters the striatal and hippocampal dopaminergic system in the adult rat brain. Eur Neuropsychopharmacol20: 895–906.
18.
InnisRBCunninghamVJDelforgeJFujitaMGjeddeAGunnRN. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab27: 1533–1539.
19.
LamarqueSTaghzoutiKSimonH (2001) Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology41: 118–129.
20.
LappinJMReevesSJMehtaMAEgertonACoulsonMGrasbyPM (2009) Dopamine release in the human striatum: motor and cognitive tasks revisited. J Cereb Blood Flow Metab29: 554–564.
21.
LidstoneSCSchulzerMDinelleKMakESossiVRuthTJ. (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry67: 857–865.
22.
LinszenDHDingemansPMLeniorME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry51: 273–279.
23.
MarcellinoDCarribaPFilipMBorgkvistAFrankowskaMBellidoI. (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology54: 815–823.
24.
MartinezDSlifsteinMBroftAMawlawiOHwangDRHuangY. (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab23: 285–300.
25.
MartinezDBroftAFoltinRWSlifsteinMHwangDRHuangY. (2004) Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology29: 1190–1202.
26.
MontgomeryAJThielemansKMehtaMATurkheimerFMustafovicSGrasbyPM (2006) Correction of head movement on PET studies: comparison of methods. J Nucl Med47: 1936–1944.
27.
MooreTHZammitSLingford-HughesABarnesTRJonesPBBurkeM. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet370: 319–328.
28.
MuschampJWSiviySM (2002) Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats. Pharmacol Biochem Behav73: 835–842.
29.
NaderMAMorganDGageHDNaderSHCalhounTLBuchheimerN. (2006) PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci9: 1050–1056.
30.
PickelVMChanJKearnCSMackieK (2006) Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol495: 299–313.
31.
PierceRCKumaresanV (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?Neurosci Biobehav Rev30: 215–238.
32.
SevySSmithGSMaYDhawanVChalyTKingsleyPB. (2008) Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl)197: 549–556.
33.
SidloZReggioPHRiceME (2008) Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels. Neurochem Int52: 80–88.
34.
SolowijNStephensRSRoffmanRABaborTKaddenRMillerM. (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA287: 1123–1131.
35.
StokesPREgertonAWatsonBReidABreenGLingford-HughesA. (2010) Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage52: 1521–1527.
36.
StokesPRMehtaMACurranHVBreenGGrasbyPM (2009) Can recreational doses of THC produce significant dopamine release in the human striatum?Neuroimage48: 186–190.
37.
TandaGPontieriFEDi ChiaraG (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science276: 2048–2050.
38.
VolkowNDChangLWangGJFowlerJSDingYSSedlerM. (2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry158: 2015–2021.
39.
VolkowNDFowlerJSWangGJBalerRTelangF (2009) Imaging dopamine’s role in drug abuse and addiction. Neuropharmacology56(Suppl 1): 3–8.
40.
VolkowNDFowlerJSWolfAPSchlyerDShiueCYAlpertR. (1990) Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry147: 719–724.
41.
VolkowNDWangGJFowlerJSLoganJGatleySJGiffordA. (1999) Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry156: 1440–1443.
42.
WatabeHEndresCJBreierASchmallBEckelmanWCCarsonRE (2000) Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med41: 522–530.
43.
ZubietaJKStohlerCS (2009) Neurobiological mechanisms of placebo responses. Ann NY Acad Sci1156: 198–210.
